New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
11:19 EDTDARADara orphan drug could make it takeover target, Triangle Business Journal says
Dara BioSciences shares jumped after the company received orphan drug designation for its experimental cancer pain treatment, which Dara CEO David Drutz said "creates a lot of interest" for potential U.S. partners, according to Triangle Business Journal. “Some have told us they might be particularly interested if we get the [orphan drug] designation,” the report quotes Drutz as stating. Reference Link
News For DARA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
14:39 EDTDARADara BioSciences granted additional 180-day period to regain NASDAQ compliance
On May 19, DARA BioSciences received a notification letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the NASDAQ Listing Qualifications Staff has granted the company's request for an additional 180-day period in which to regain compliance with the minimum $1.00 bid price per share requirement. The NASDAQ Listing Qualifications Staff's determination to grant the additional 180 day compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the NASDAQ Capital Market, with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the additional 180-day compliance period by effecting a reverse stock split, if necessary.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use